Bain Capital Public Equity Management LLC cut its stake in shares of Sangamo Therapeutics Inc (NASDAQ:SGMO) by 37.1% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 128,184 shares of the biopharmaceutical company’s stock after selling 75,607 shares during the quarter. Bain Capital Public Equity Management LLC owned approximately 0.15% of Sangamo Therapeutics worth $2,102,000 as of its most recent SEC filing.
Several other large investors also recently bought and sold shares of the company. BlackRock Inc. grew its holdings in shares of Sangamo Therapeutics by 2.1% during the fourth quarter. BlackRock Inc. now owns 6,871,509 shares of the biopharmaceutical company’s stock valued at $112,691,000 after purchasing an additional 138,348 shares during the last quarter. State Street Corp grew its holdings in Sangamo Therapeutics by 51.6% in the 2nd quarter. State Street Corp now owns 1,868,285 shares of the biopharmaceutical company’s stock worth $16,441,000 after buying an additional 636,296 shares in the last quarter. Alexandria Capital LLC bought a new position in Sangamo Therapeutics in the 4th quarter worth approximately $15,179,000. Goldman Sachs Group Inc. grew its holdings in Sangamo Therapeutics by 58.4% in the 4th quarter. Goldman Sachs Group Inc. now owns 911,512 shares of the biopharmaceutical company’s stock worth $14,948,000 after buying an additional 336,107 shares in the last quarter. Finally, Geode Capital Management LLC grew its holdings in Sangamo Therapeutics by 2.3% in the 4th quarter. Geode Capital Management LLC now owns 840,104 shares of the biopharmaceutical company’s stock worth $13,777,000 after buying an additional 19,087 shares in the last quarter. 65.74% of the stock is owned by institutional investors.
A number of equities analysts recently issued reports on SGMO shares. Barclays reissued a “buy” rating and issued a $30.00 price objective on shares of Sangamo Therapeutics in a report on Sunday, February 25th. Jefferies Group reissued a “buy” rating on shares of Sangamo Therapeutics in a report on Friday, February 23rd. Piper Jaffray Companies set a $25.00 price objective on Sangamo Therapeutics and gave the stock a “buy” rating in a report on Wednesday, January 3rd. BidaskClub raised Sangamo Therapeutics from a “hold” rating to a “buy” rating in a report on Friday, December 29th. Finally, Zacks Investment Research raised Sangamo Therapeutics from a “hold” rating to a “buy” rating and set a $14.00 price objective for the company in a report on Wednesday, November 15th. Three equities research analysts have rated the stock with a hold rating, five have issued a buy rating and one has issued a strong buy rating to the company. The stock currently has a consensus rating of “Buy” and a consensus target price of $20.50.
Sangamo Therapeutics (NASDAQ:SGMO) last released its earnings results on Thursday, February 22nd. The biopharmaceutical company reported ($0.15) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.18) by $0.03. The firm had revenue of $13.08 million during the quarter, compared to the consensus estimate of $11.10 million. Sangamo Therapeutics had a negative return on equity of 31.44% and a negative net margin of 149.23%. The firm’s revenue for the quarter was up 46.6% compared to the same quarter last year. During the same period in the prior year, the firm posted ($0.14) earnings per share. analysts anticipate that Sangamo Therapeutics Inc will post 0.04 earnings per share for the current fiscal year.
In other Sangamo Therapeutics news, VP Curt A. Herberts III sold 15,000 shares of the company’s stock in a transaction that occurred on Wednesday, January 3rd. The stock was sold at an average price of $17.26, for a total value of $258,900.00. Following the completion of the sale, the vice president now directly owns 13,015 shares in the company, valued at $224,638.90. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, VP Edward R. Conner sold 5,000 shares of the company’s stock in a transaction that occurred on Tuesday, March 6th. The stock was sold at an average price of $24.78, for a total value of $123,900.00. The disclosure for this sale can be found here. Insiders sold 90,403 shares of company stock valued at $1,907,369 over the last 90 days. 5.50% of the stock is currently owned by insiders.
Sangamo Therapeutics Profile
Sangamo Therapeutics, Inc, formerly Sangamo BioSciences, Inc, is a clinical-stage biotechnology company. The Company is focused on translating science into genomic therapies that transform patients’ lives using the Company’s platform technologies in genome editing, gene therapy, gene regulation and cell therapy.
Want to see what other hedge funds are holding SGMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Sangamo Therapeutics Inc (NASDAQ:SGMO).
Receive News & Ratings for Sangamo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sangamo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.